CAM
HRMY icon

Cresset Asset Management’s Harmony Biosciences HRMY Stock Holding History

Cresset Asset Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.73M Buy
102,479
+30,044
+41% +$948K 0.01% 487
2026
Q1 		$2.03M Buy
72,435
+5,062
+8% +$166K 0.01% 558
2025
Q4 		$2.52M Buy
67,373
+221
+0.3% +$7.27K 0.01% 504
2025
Q3 		$1.85M Buy
67,152
+315
+0.5% +$10.9K 0.01% 557
2025
Q2 		$2.11M Sell
66,837
-2,124
-3% -$68.3K 0.01% 486
2025
Q1 		$2.29M Sell
68,961
-2,804
-4% -$101K 0.01% 503
2024
Q4 		$2.47M Buy
71,765
+7,557
+12% +$260K 0.01% 492
2024
Q3 		$2.57M Buy
64,208
+3,830
+6% +$135K 0.01% 682
2024
Q2 		$1.82M Buy
60,378
+9,516
+19% +$286K 0.01% 763
2024
Q1 		$1.71M Buy
+50,862
New +$1.63M 0.01% 723

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cresset Asset Management's HRMY Position: Q2 2026 in Review

Cresset Asset Management increased its Harmony Biosciences (HRMY) stake by 41% in Q2 2026, buying an estimated $948K and bringing the position to 102,479 shares worth $3.73M. The position accounts for 0.01% of the portfolio, ranked #487.

Cresset Asset Management first reported a position in HRMY in Q1 2024 and has held it in 10 quarters since. 328 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Cresset Asset Management held 102,479 shares of Harmony Biosciences worth $3.73M as of Q2 2026.
  • Cresset Asset Management bought 30,044 Harmony Biosciences shares in Q2 2026, an estimated $948K.
  • Harmony Biosciences made up 0.01% of Cresset Asset Management's portfolio in Q2 2026, its #487 holding.
  • Cresset Asset Management first reported a position in Harmony Biosciences in Q1 2024 and has held it in 10 quarters since.
  • 328 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.